2018
Patient Perspectives on Adherence to the New Hepatitis C Antiviral Medications: ‘A New Lease on Life’
Giordano N, Brinn A, Garcia-Tsao G, Martino S. Patient Perspectives on Adherence to the New Hepatitis C Antiviral Medications: ‘A New Lease on Life’. The Qualitative Report 2018 DOI: 10.46743/2160-3715/2018.2740.Peer-Reviewed Original ResearchMedication adherenceBurden of HCVCourse of treatmentActing antiviralsHepatitis CAntiviral medicationsNew DAAsTreatment coursePatient's perspectiveClinical implicationsSemi-structured interviewsAdherenceVeteransTreatmentOpen coding methodPositive outcomesHCVMedicationsPatientsMajor themesAntiviralsPurposive samplingCourse
2015
231/356 Statin Use and the Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis
Mohanty A, Tate J, Garcia-Tsao G. 231/356 Statin Use and the Risk of Decompensation and Death in Veterans With Hepatitis C-Related Compensated Cirrhosis. Gastroenterology 2015, 148: s-972-s-973. DOI: 10.1016/s0016-5085(15)33322-9.Peer-Reviewed Original ResearchO072 : Statin use significantly decreases decompensation and death in veterans with hepatitis C-related compensated cirrhosis
Mohanty A, Tate J, Garcia-Tsao G. O072 : Statin use significantly decreases decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Journal Of Hepatology 2015, 62: s226-s227. DOI: 10.1016/s0168-8278(15)30086-6.Peer-Reviewed Original Research
2014
Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic Factors
Sanchez M, Augustin S, Balakrishnan M, Re V, Tate J, Garcia-Tsao G. Su1050 Statin Use Is Associated With Sustained Virological Response in Patients With Hepatitis C Treated With Pegylated Interferon and Ribavirin, Independent of Host Metabolic Factors. Gastroenterology 2014, 146: s-974-s-975. DOI: 10.1016/s0016-5085(14)63541-1.Peer-Reviewed Original Research
2013
Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise
Belcher JM, Parikh CR, Garcia–Tsao G. Acute Kidney Injury in Patients With Cirrhosis: Perils and Promise. Clinical Gastroenterology And Hepatology 2013, 11: 1550-1558. PMID: 23583467, PMCID: PMC3840046, DOI: 10.1016/j.cgh.2013.03.018.Commentaries, Editorials and LettersConceptsCreatinine levelsSodium levelsRenal Disease Study equationPacked red blood cellsTotal serum bilirubin levelsAcute kidney injurySerum creatinine levelsMental status changesRenal tubular epithelial cellsSerum sodium levelsChronic liver diseaseGlomerular filtration rateInternational normalization ratioModification of DietIntensive care unitUrine sodium levelSerum bilirubin levelsFresh frozen plasmaChronic alcohol abuseTubular epithelial cellsHepatitis CKidney injuryRed blood cellsBlood pressureFractional excretion
2003
553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis?
Nagula S, Jain D, Groszmann R, Garcia-Tsao G. 553 Histologic-hemodynamic correlations in hepatitis C and other chronic liver diseases — is there a histologically mild and severe cirrhosis? Hepatology 2003, 38: 426-427. DOI: 10.1016/s0270-9139(03)80595-5.Peer-Reviewed Original Research
2002
Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point?
Burroughs A, Groszmann R, Bosch J, Grace N, Garcia-Tsao G, Patch D, Garcia-Pagan J, Dagher L. Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 2002, 50: 425. PMID: 11839726, PMCID: PMC1773121, DOI: 10.1136/gut.50.3.425.Peer-Reviewed Original ResearchConceptsHepatic venous pressure gradientChronic hepatitis CVenous pressure gradientHepatitis CAntiviral therapyEnd pointChronic hepatitis C.Major healthcare problemBest end pointHepatitis C.HVPG measurementTherapeutic benefitTherapeutic evaluationTherapyHealthcare problemPatientsPressure gradientResponse